KR20230093522A - 류마티스 관절염의 치료를 위한 조성물 및 방법 - Google Patents

류마티스 관절염의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230093522A
KR20230093522A KR1020237019726A KR20237019726A KR20230093522A KR 20230093522 A KR20230093522 A KR 20230093522A KR 1020237019726 A KR1020237019726 A KR 1020237019726A KR 20237019726 A KR20237019726 A KR 20237019726A KR 20230093522 A KR20230093522 A KR 20230093522A
Authority
KR
South Korea
Prior art keywords
antibody
subject
seq
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237019726A
Other languages
English (en)
Korean (ko)
Inventor
데보라 바우어
알렉산더 바디
닐 그레이엄
용 린
제니 파리노
라울 파텔
자넷 반 아델스버그
휴버트 반 훅스트라텐
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Publication of KR20230093522A publication Critical patent/KR20230093522A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237019726A 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법 Ceased KR20230093522A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16305253.3 2016-03-07
EP16170664 2016-05-20
EP16170664.3 2016-05-20
EP16306111 2016-09-05
EP16306111.2 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis
KR1020187028624A KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028624A Division KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20230093522A true KR20230093522A (ko) 2023-06-27

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237019726A Ceased KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법
KR1020187028624A Ceased KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187028624A Ceased KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (2) KR20230093522A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG10202012182YA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TW202419103A (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112020010761A2 (pt) * 2017-11-30 2020-11-24 Bio-Thera Solutions, Ltd. formulação líquida de anticorpo humanizado para o tratamento de doenças relacionadas à il-6
MX2021002422A (es) * 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
TW202521583A (zh) * 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
TW202106712A (zh) * 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
MA56116A (fr) 2019-06-04 2022-04-13 Stefano Fiore Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
CN117858722A (zh) * 2021-08-18 2024-04-09 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法

Also Published As

Publication number Publication date
JP2023011711A (ja) 2023-01-24
JP7166925B2 (ja) 2022-11-08
TW201808993A (zh) 2018-03-16
IL261515B2 (en) 2024-04-01
TW202419103A (zh) 2024-05-16
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
MX2023014841A (es) 2024-01-15
SG11201807614SA (en) 2018-10-30
TW202239767A (zh) 2022-10-16
IL261515A (en) 2018-10-31
BR112018067851A2 (pt) 2019-02-05
EP3426295A1 (en) 2019-01-16
WO2017155990A1 (en) 2017-09-14
US20190100585A1 (en) 2019-04-04
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
NZ746988A (en) 2023-10-27
JP7745529B2 (ja) 2025-09-29
JP2019507775A (ja) 2019-03-22
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
EA201892005A1 (ru) 2019-02-28
CA3016880A1 (en) 2017-09-14
SG10202012182YA (en) 2021-01-28
TN2018000312A1 (en) 2020-01-16
AU2024203011A1 (en) 2024-07-11
CR20180465A (es) 2019-03-04
MX2018010815A (es) 2019-01-10
CN109069642A (zh) 2018-12-21
KR20180114955A (ko) 2018-10-19
IL308539A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
CN114617962A (zh) 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
JP2024161517A (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
US11491222B2 (en) Method of treating lower back pain
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
EP4175986A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
HK40072292A (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601